The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Beyond outsourcing: Turning your CDMO into a value-creation engine for biopharma assets
This webinar explores trends in in- and out-licensing and examines how a strategic CDMO partnership can help de-risk drug development and maximize the value of biopharma assets.
As biotechnology and pharmaceutical companies seek to maximize their commercial potential, minimize drug development risk, and expand market reach, in- and out-licensing have become essential components of modern business strategy. Whether you're a small biotech startup or a large pharmaceutical company, understanding today's licensing landscape is critical to making informed decisions and driving business success for the long-term.
Global outsourcing partners play a vital role in both early- and late-stage development by generating the data, technologies, and manufacturing processes that support successful clinical outcomes and strengthen asset evaluation. With their breadth and depth of expertise, global CDMOs are uniquely positioned to support risk assessment, gap analysis, and due diligence—helping enhance asset value throughout the development lifecycle.
Explore the importance of innovation, collaboration, and the strategic exchange of assets and technologies
This on-demand webinar explores current licensing trends and demonstrates how a strategic CDMO partnership can help innovators maximize asset value by accelerating development timelines, reducing risk, and optimizing resources.
Watch this webinar to learn about:
- Global trends in the in- and out-licensing of new molecular entities (NMEs)
- Strategies for successful licensing and partnering across biotech and pharma
- Key factors that drive asset value and licensing success over the long term
- How global CDMO partnerships enhance asset value across every stage
- Flexible financing solutions that help reduce risk on the journey to market
Speakers:
Anil Kane, PhD, MBA
Global Head of Technical & Scientific Affairs
Pharma Services, Thermo Fisher Scientific
Dr. Kane has more than 30 years of experience in the science and business of advancing molecules through the entire drug development process. His extensive expertise spans early-stage development through scale-up and commercial manufacturing of drug products and includes technical transfers across global sites and drug lifecycle management. Dr. Kane received his bachelor's, master's, and PhD degrees from the Bombay College of Pharmacy, University of Bombay, India, and served as a postdoctoral fellow at the University of Cincinnati College of Pharmacy in Ohio. He also earned an Executive MBA from the Richard Ivey School of Business at the University of Western Ontario, Canada. Dr. Kane is a member of several international pharmaceutical professional organizations and is a frequent speaker at industry events. He has published numerous articles in international journals and delivered presentations at meetings and conferences around the world.
Jill Kniebel, MBA
Senior Manager, Global Financial Solutions
Pharma Services, Thermo Fisher Scientific
With nearly 20 years at Thermo Fisher Scientific, Jill currently serves as Senior Manager on the Global Financial Solutions team, where she specializes in developing innovative equipment and service financing solutions for customers across the biotech, healthcare, and life sciences industries. Throughout her career, Jill has partnered with commercial and operational teams to create flexible financing strategies that help accelerate scientific innovation and improve customer access to critical technologies and services. Her deep industry expertise and customer-focused approach have made her a trusted advisor, supporting customer growth and advancing outcomes globally. Jill received her Bachelor of Science degree from the University of Massachusetts and her MBA from Simmons University.